Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALOGLIPTIN vs ALPELISIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ALOGLIPTIN vs ALPELISIB: Safety Overview

Metric ALOGLIPTIN ALPELISIB
Total FAERS Reports 1,385 8,419
Deaths Reported 122 1,271
Death Rate 8.8% 15.1%
Hospitalizations 567 1,705
Average Patient Age 69.0 yrs 58.8 yrs
% Female Patients 41.0% 94.7%
FDA Approval Date Jan 25, 2013 Apr 24, 2024
Manufacturer Padagis Israel Pharmaceuticals Ltd Novartis Pharmaceuticals Corporation
Route ORAL ORAL
Marketing Status Prescription Prescription